Adenosine-dopamine interactions in the central nervous system (CNS) have been studied for many years in view of their relevance for disorders of the CNS and their treatments. The discovery of adenosine and dopamine receptor containing receptor mosaics (RM, higher-order receptor heteromers) in the striatum opened up a new understanding of these interactions. Initial findings indicated the existence of A2AR-D2R heterodimers and A1R-D1R heterodimers in the striatum that were followed by indications for the existence of striatal A2AR-D3R and A2AR-D4R heterodimers. Of particular interest was the demonstration that antagonistic allosteric A2A-D2 and A1-D1 receptor-receptor interactions take place in striatal A2AR-D2R and A1R-D1R heteromers. As a consequence, additional characterization of these heterodimers led to new aspects on the pathophysiology of Parkinson's disease (PD), schizophrenia, drug addiction, and l-DOPA-induced dyskinesias relevant for their treatments. In fact, A2AR antagonists were introduced in the symptomatic treatment of PD in view of the discovery of the antagonistic A 2AR-D2R interaction in the dorsal striatum that leads to reduced D2R recognition and Gi/o coupling in striato-pallidal GABAergic neurons. In recent years, indications have been obtained that A2AR-D2R and A1R-D1R heteromers do not exist as heterodimers, rather as RM. In fact, A 2A-CB1-D2 RM and A2A-D 2-mGlu5 RM have been discovered using a sequential BRET-FRET technique and by using the BRET technique in combination with bimolecular fluorescence complementation. Thus, other pathogenic mechanisms beside the well-known alterations in the release and/or decoding of dopamine in the basal ganglia and limbic system are involved in PD, schizophrenia and drug addiction. In fact, alterations in the stoichiometry and/or topology of A 2A-CB1-D2 and A2A-D 2-mGlu5 RM may play a role. Thus, the integrative receptor-receptor interactions in these RM give novel aspects on the pathophysiology and treatment strategies, based on combined treatments, for PD, schizophrenia, and drug addiction. © 2010 Blackwell Publishing Ltd.

Adenosine-dopamine interactions in the pathophysiology and treatment of cns disorders

TANGANELLI, Sergio;
2010

Abstract

Adenosine-dopamine interactions in the central nervous system (CNS) have been studied for many years in view of their relevance for disorders of the CNS and their treatments. The discovery of adenosine and dopamine receptor containing receptor mosaics (RM, higher-order receptor heteromers) in the striatum opened up a new understanding of these interactions. Initial findings indicated the existence of A2AR-D2R heterodimers and A1R-D1R heterodimers in the striatum that were followed by indications for the existence of striatal A2AR-D3R and A2AR-D4R heterodimers. Of particular interest was the demonstration that antagonistic allosteric A2A-D2 and A1-D1 receptor-receptor interactions take place in striatal A2AR-D2R and A1R-D1R heteromers. As a consequence, additional characterization of these heterodimers led to new aspects on the pathophysiology of Parkinson's disease (PD), schizophrenia, drug addiction, and l-DOPA-induced dyskinesias relevant for their treatments. In fact, A2AR antagonists were introduced in the symptomatic treatment of PD in view of the discovery of the antagonistic A 2AR-D2R interaction in the dorsal striatum that leads to reduced D2R recognition and Gi/o coupling in striato-pallidal GABAergic neurons. In recent years, indications have been obtained that A2AR-D2R and A1R-D1R heteromers do not exist as heterodimers, rather as RM. In fact, A 2A-CB1-D2 RM and A2A-D 2-mGlu5 RM have been discovered using a sequential BRET-FRET technique and by using the BRET technique in combination with bimolecular fluorescence complementation. Thus, other pathogenic mechanisms beside the well-known alterations in the release and/or decoding of dopamine in the basal ganglia and limbic system are involved in PD, schizophrenia and drug addiction. In fact, alterations in the stoichiometry and/or topology of A 2A-CB1-D2 and A2A-D 2-mGlu5 RM may play a role. Thus, the integrative receptor-receptor interactions in these RM give novel aspects on the pathophysiology and treatment strategies, based on combined treatments, for PD, schizophrenia, and drug addiction. © 2010 Blackwell Publishing Ltd.
2010
Fuxe, K; Marcellino, D; Borroto Escuela, Do; Guescini, M; Fernández Dueñas, V; Tanganelli, Sergio; Rivera, A; Ciruela, F; Agnati, L. F.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/1508714
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 140
  • ???jsp.display-item.citation.isi??? 127
social impact